Coeptis Therapeutics (COEP) Regains Nasdaq Complianc

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) announced today that it has received a notification letter from the Nasdaq Hearings Panel (the "Panel") granting its request for continued listing on The Nasdaq Stock Market ("Nasdaq") through January 15, 2025, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2).

As previously disclosed, on January 29, 2024, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Company's common stock, for the last 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement") for continued listing as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Original Notice"). At that time, the Company was provided a compliance period of 180 calendar days from the date of the Original Notice, or until July 29, 2024, to regain compliance with the Minimum Bid Price Requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

On September 12^th, Coeptis presented a plan before the Panel to address the minimum bid price requirement, including its intent to implement a reverse stock split. The Panel issued its decision on September 17^th with the extension granted.

"We are pleased with the decision from Nasdaq to grant us our extension," said Dave Mehalick President and Chief Executive Officer of Coeptis. "We look forward to regaining and maintaining compliance with Nasdaq's continued listing requirements and continuing to focus on our goal of improving patient outcomes."

You May Also Be Interested In

• TransUnion CFO Todd Cello to resign at end of 2026
• AMC Entertainment prices $2.85B in new debt to refinance existing loans
• Cytek Biosciences adds cloud analysis tool to its digital platform